Twist Bioscience Launches New NGS Solutions, Highlights Customers at 2020 Advances in Genome Biology and Technology Conference

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the Twist Targeted Methylation Sequencing Solution to study methylation pattern changes in a wide range of research fields including cancer, epigenetics and non-invasive prenatal testing is now available for early access customers. In addition, the company announced the launch of its Twist Comprehensive Exome Panel, an optimal NGS target enrichment solution that includes more than 99% of protein coding genes.